# Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer

> **NCT03523572** · PHASE1 · COMPLETED · sponsor: **Daiichi Sankyo** · enrollment: 86 (actual)

## Conditions studied

- Breast Cancer
- Urothelial Carcinoma

## Interventions

- **DRUG:** Trastuzumab deruxtecan
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03523572
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-02
- **Primary completion:** 2021-07-22
- **Final completion:** 2023-09-12
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2025-01-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03523572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03523572, "Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT03523572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*